Orwah Al-Khalili, MD
Rheumatology · Peoria, AZNPI 1457666026
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,020 of the $20,147 with a category attached, or 89.4%. It is spread thinly across 41 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 816 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$4K
- AbbVie$4K
- Amgen$3K
- AstraZeneca$1K
- GSK$881
- Novartis$850
- plus $6K from 35 others
What the payments were for
- Consulting fees$1,6658%
- Grants$2401%
- Food & beverage$18,02089%
- Education$2221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 80 | $3,978 |
| AbbVie | 133 | $3,932 |
| Amgen(2 entities) | 142 | $2,732 |
| AstraZeneca(2 entities) | 59 | $1,292 |
| GSK | 41 | $881 |
| Novartis | 42 | $850 |
| Mallinckrodt Hospital Products Inc. | 34 | $812 |
| Johnson & Johnson | 51 | $786 |
| Radius Health, Inc. | 30 | $645 |
| Boehringer Ingelheim | 23 | $501 |
| Sanofi | 11 | $485 |
| E.r. Squibb & Sons, L.L.C. | 22 | $428 |
| Fresenius Kabi USA, LLC | 20 | $426 |
| Pfizer | 28 | $409 |
| ANI Pharmaceuticals, Inc. | 22 | $352 |
| Lilly USA, LLC | 14 | $248 |
| Actelion Pharmaceuticals US, Inc. | 9 | $234 |
| Sobi, Inc | 9 | $188 |
| Organon | 8 | $143 |
| Aurinia Pharma U.S., Inc. | 3 | $142 |
| Genentech USA, Inc. | 4 | $80 |
| Tersera Therapeutics LLC | 4 | $74 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $70 |
| Kyowa Kirin, Inc. | 2 | $55 |
| Celltrion USA Inc. | 2 | $44 |
| Merck | 2 | $43 |
| Octapharma USA, Inc. | 1 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Biogen | 1 | $27 |
| Bioventus LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Sandoz | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Nevro Corp. | 1 | $15 |
| Bayer | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Avanos Medical | 1 | $14 |
| Qiagen, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,147 in reported general payments places this provider in the 75th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 278 | $8,839 |
| Mycophenolate Mofetil | 55 | $6,798 |
| MethotrexateMethotrexate Sodium | 424 | $6,755 |
| Leucovorin Calcium | 49 | $1,736 |
| Leflunomide | 38 | $1,630 |
| Gabapentin | 132 | $1,437 |
| Celecoxib | 68 | $1,241 |
| Prednisone | 179 | $1,090 |
| Clobetasol Propionate | 20 | $1,038 |
| Colchicine | 22 | $809 |
| Sulfasalazine | 29 | $728 |
| Tramadol Hcl | 104 | $642 |
| Fluconazole | 14 | $530 |
| Diclofenac Sodium | 28 | $528 |
| Alendronate Sodium | 88 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $80922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Peoria
- Joy SchechtmanPeoria$860K
- Varun BhallaPeoria$7K
- Ravi BhallaPeoria$5K
- Terrence PrasadPeoria$2K
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.